Steven Brodie, Sally Agersborg, Jennifer Balliet

Apr 23, 2015

NeoGenomics has promoted three executives, including Steven Brodie to chief scientific officer and medical director in Ft. Myers, Fla. He joined the company in 2011 as director of cytogenetics and is currently director of molecular genetics and cytogenetics for NeoGenomics' Florida operations. 

Also, Sally Agersborg was promoted to director of hematopathology. She joined NeoGenomics in 2011 as a hematopathologist and currently is the medical director for the company's Irvine, Cal.-based facility, a title she will retain. 

Lastly, Jennifer Balliet was promoted to vice president of human resources. She joined NeoGenomics in 2008 and currently is director of HR.

More Like This

Jun 21, 2018

Garrett Lam

Garrett Lam will join Sera Prognostics as chief medical officer starting Sept. 4. He will direct all clinical development activities for the firm and direct a group of clinical operations professionals in support of the firm's collaborations. Lam is currently a professor and chairman of obstetrics and gynecology at the University of Tennessee College of Medicine-Chattanooga. Lam replaces Durlin Hickok, who has been Sera's CMO since 2011. Hickok will continue as an advisor to Sera. 

Jun 20, 2018

Kenneth Bloom

Kenneth Bloom has become chief medical officer of advanced pathology and genomic services at Invicro and Ambry Genetics, both part of Konica Minolta. Previously, he was president and head of oncology and immunotherapy at Human Longevity, and before that, chief medical officer of in vitro diagnostics, life sciences at General Electric. He also served as president and CEO of the medical group of Clarient Pathology Services, which was acquired by GE. Prior to that, he held various academic positions, including director of laboratory operations and chief information officer at the Rush Cancer Institute, clinical professor of pathology at the University of Southern California Keck School of Medicine, and associate professor of pathology at Rush Medical College. Bloom holds an MD from Rush Medical College and a BA from Grinnell College.

Jun 18, 2018

Joseph Caruso

LexaGene has appointed Joseph Caruso to the its board of directors. Caruso currently serves as a member of the board of directors and operating committee at Endocellutions. Caruso was previously CEO and chairman of Palomar Medical Technology until the firm's sale in 2013. 

Jun 15, 2018

Lihau Yu

Eisai announced today that it has appointed Lihau as president and chief data sciences officer of H3 Biomedicine, the cancer genomics-based drug discovery company of Eisai. Yu will be responsible for the overall scientific and business direction of H3, where she joined H3 in 2011. Yu previously spent 12 years at AstraZeneca. 

Jun 13, 2018

Lawrence Firestone

Akonni Biosystems has appointed Lawrence Firestone to the role of executive vice president and CFO to bring the company through the commercialization phase of its business plan. Firestone has previously served as CEO, CFO, and COO in various technology firms.

Jun 13, 2018

Rohan Hastie, John Ryals,

Rohan Hastie was named president and CEO of Metabolon. He replaces John Ryals, who retired from those posts, but will remain on the company's board. Ryals has been president, CEO, and a board member of Metabolon since April 2002, when he cofounded the firm. 

Hastie joined Metabolon in September 2017 as chief business officer. Before that, he was president of consulting firm Arrow Life Sciences & Healthcare. He also has held leadership positions in diagnostics and corporate development at Hologic, where he was most recently president of Hologic Diagnostic Solutions.

Jun 12, 2018

Michael McCartney

Cancer Genetics has appointed Michael McCartney its chief commercial officer, effective immediately. McCartney was previously CEO of SciKon Innovation, an early-stage life science company. Before that, he was SciKon's COO. He has more than 20 years of experience in the life science space including stints at Roche, Siemens, and Abbott. 

Jun 08, 2018

Gerald Herman

Bruker announced that it has hired Gerald Herman as its new CFO. He replaces Anthony Mattacchione, whose resignation was announced in February. Herman joined Bruker in 2016 as VP and corporate controller, and has been serving as interim CFO since March 2018. He previously served a corporate VP - Clinical Operations of Parexel International from 2014 to February 2016, and as corporate VP and controller-finance of Parexel from 2008 to 2013. Prior to 2008, he was VP - corporate controller of Presstek.

Jun 06, 2018

Michael Hultner

PetaGene has appointed Michael Hultner as senior vice president and general manager of US operations. Hultner will be responsible for growng the company's commercial operations and client support in the US while contributing to the strategic direction of PetaGene and its products, which include PetaSuite and PetaSuite Cloud Edition for genomic data compression. Hultner joins PetaGene from Seven Bridges, where he was chief strategy officer and general manager of national programs. Prior to that he was chief scientist at Leidos, and he has held several executive positions at Lockheed Martin Health & Life Sciences.

Jun 06, 2018

Bob Englert, Steve Crouse

Vortex Biosciences has appointed Bob Englert as its new CEO. Englert, who was previously the firm's chief technology officer, replaces exiting CEO Gene Walther, who has resigned to pursue other interests and will step down both from his position as CEO and as a member of the company's board.

Englert has over 25 years of experience in medical devices and life sciences, with a particular focus on IVD, point of care, and digital health solutions. Before joining Vortex, he served as CEO and founder of Biomedtrics, a diabetes data management company, and prior to that he was COO of Pelikan Technologies. Earlier in his career, Englert also held multiple senior roles at Abbott Laboratories. He holds a BS in biology from the University of Illinois Urbana-Champaign.

Vortex also said that Steve Crouse, who has been the company's chief commercial officer since March 2016, will now assume the position of chief operating officer. Prior to joining Vortex, Crouse served as senior vice president of sales and marketing at Freeslate, a company focused on providing laboratory automation to chemical and pharmaceutical companies.

Jun 01, 2018

Ben Ho Park

Vanderbilt has announced that Ben Ho Park has been named co-leader of the breast cancer research program, director of the precision oncology, and associate director for translational research at the Vanderbilt-Ingram Cancer Center. Park, who will assume the post Sept. 1, succeeds Carlos Arteaga. Park currently serves as professor of oncology in the bresat and ovarian cancer program, associate director for research training and education, and member of the executive oversight committee at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. Park received his undergraduate degree from the University of Chicago, followed by dual training at the University of Pennsylvania School of Medicine. 

May 31, 2018

Ted Goldstein

Precision medicine informatics company GNS Healthcare has named bioinformatician and biomedical engineer Ted Goldstein to its strategic advisory board. Goldstein, scientific program director of computational health at the University of California, San Francisco, is leading development of a machine learning-based comprehensive cancer diagnosis and treatment model for the university. He previously was vice president of developer tools at Apple and an e-commerce hardware developer for Sun Microsystems. 

May 29, 2018

Craig Venter

Craig Venter said last week that he is retiring from Human Longevity, a company he co-founded and where he serves as chairman and CEO. Venter said in a Tweet that he will be returning to the J. Craig Venter Institute, which he founded in 2006, "to continue my work."

May 25, 2018

Cynthia Collins

DermTech, a developer of non-invasive molecular dermatology tests, has appointed Cynthia Collins to its board of directors. Collins most recently served as CEO of Human Longevity. She has also been CEO/GM of GE Healthcare's cell therapy business, lab businesses, and Clarient Diagnostics. Prior to GE, Collins was president and CEO of GenVec. Before that she was group vice president for the cellular analysis business at Beckman Coulter. She has also held executive positions with Sequoia Pharmaceuticals and Clinical Micro Sensors, a subsidiary of Motorola.

May 24, 2018

Craig Mak

Arbor Biotechnologies has appointed Craig Mak as director of strategy. Prior to joining Arbor, Mak served as the editor of Cell Systems, as a senior editor at Nature Biotechnology, and as a software engineer at Sun Microsystems. 

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.